Aim: The aims of the study are to determine the incidence of oral mucositis, the stage of the condition, risk factors, and other oral complications in patients receiving outpatient chemotherapy and to evaluate the factors that have an impact on these.
• Mucositis is a painful lesion and afflicts feeding, quality of life, and treatment process of the patient.
• The applications of basic oral care to patients receiving chemotherapy have an impact on the incidence and severity of oral mucositis and contribute to prevent bacterial colonization in the context of mucositis.
What this paper adds?
• Oral mucositis affects outpatients receiving chemotherapy as much as it does inpatients.
• Advanced age, lack of appetite, duration of chemotherapy, and the presence of oral complications are effective factors in the development of oral mucositis.
• Patients are unable to adequately prevent oral mucositis and carry out oral care.
The implications of this paper:
• Patients who will be receiving outpatient chemotherapy should undergo an oral examination before, during, and after their therapy and should under all circumstances receive education.
The copyright line for this article was changed on 11 January 2019, after original online publication.
• The relationship between oral mucositis and the form, dose, and duration of the drugs used in chemotherapy should be taken into consideration in the case of individuals undergoing outpatient chemotherapy.
• Mucositis prevention and treatment should not be underestimated in patients treated in the outpatient setting.
| INTRODUCTION
The gastrointestinal tract is the region most affected by the cytotoxic impact of cancer therapy, and the first changes are noticed in the oral cavity. The direct and indirect effects of chemotherapy compromise mucosal integrity of cells, leading to oral mucositis (OM).
Chemotherapy has more of an impact on the motile nonkeratinized mucosa of the soft palate, the cheeks and lips, the ventral surface of the tongue, and the floor of the mouth (Sonis, 2004) . Studies have reported that the prevalence of OM is 6% to 75% among cancer patients who undergo chemotherapy (Chen, 2008; Trotti et al., 2003; Wilberg, Hjermstad, Ottesen, & Herlofson, 2014; Wuketich, Hienz, & Marosi, 2012) .
Changes in the oral mucosa may lead to a disruption in the patient's eating and swallowing capabilities, to pain, reduced appetite and malnutrition, a disruption in treatment, an extension of hospitalization, increased costs, and, in some patients, to life-threatening septicemia (Cheng et al., 2010; Raber-Durlacher et al., 2004; Wuketich et al., 2012) . Cheng (2007) reports that patients being treated for cancer frequently complain of symptoms of dryness of the mouth (72%), a change in taste (63%), dysphagia (40%), and weight loss (57%) (Cheng, 2007) . Elting et al. (2003) assert in their study that in patients receiving myelosuppressive chemotherapy who develop oral mucositis, a regimen of reducing the dose is adopted in all stages of the condition and that this decision is likely made because of attacks of infection related to mucositis or due to bleeding, neutropenia or thrombocytopenia, or many other interconnected associated factors (Elting et al., 2003) .
The clinical practice guide MASCC/ISOO 2014 sets out oral care protocols and steps health professionals can take to prevent and treat oral mucositis that accompanies cancer therapy. In this guideline, the use of cryotherapy, recombinant human keratinocyte growth factor (palifermin), and low-energy laser therapy is recommended to the prevention of oral mucositis (Lalla et al., 2014) .
Carrying out regular follow-ups of patients receiving chemotherapy makes it possible to evaluate and understand the risk factors causing the development of mucositis (Çavuşoğlu, 2007; Shankar et al., 2017) . In this context, an interdisciplinary approach (with the participation of nurses, physicians, dentists, dental hygienists, dieticians, pharmacists, and others as relevant) will prevent the development of OM and/or treat the condition (da Silva Santos et al., 2011; McGuire et al., 2013) have reported a decrease the time elapsed of OM in patients with OM receiving oral care before haematopoetic stem cell transplantation (da Silva Santos et al., 2011) . In another study, it has been observed that oral care can reduce the severity and incidence of OM (Coracin et al., 2013) . On the other hand, some reports have
shown that oral problems are not adequately addressed in cancer patients undergoing chemotherapy, that these problems are inadequately treated due to being ignored by both doctors and nurses, and that there is a lack of nursing interventions for cancer patients who have oral mucositis (Araújo et al., 2015; Daniel, Damato, & Johnson, 2004; Honnor & Law, 2002) . These circumstances may even be at more serious levels in the case of individuals receiving outpatient chemotherapy.
| METHODS

| Aim
The aims of this study were to determine the incidence of OM, the stage of the condition, risk factors, and other oral complications in patients receiving outpatient chemotherapy and to evaluate the sociodemographic and clinical characteristics that have an impact on these.
| Study design and sample
This was a descriptive study carried out in the Daily Chemotherapy Unit of a University Hospital from February to April 2015. The study sample consisted of patients diagnosed with lung, breast, and gastrointestinal tract (stomach, liver, pancreas, colon, rectum) cancers. The incidence of chemotherapy-induced oral mucositis was accepted as 75.4% (Chen, 2008) ; the sample number was calculated as 147 persons, at a power of 90% and a confidence interval of 95% in the OpenEpi program (http:// www.openepi.com/SampleSize/SSPropor.htm).
All patients were fully conscious, able to communicate, older than 18 years, undergoing their second course of chemotherapy, and volunteered to participate in the study. Patients were interviewed between 08 and 12 hours on 3 days a week (Monday, Wednesday, and Friday) by visiting researchers.
| Ethical considerations
The protocol of the study was approved by the ethical review boards at the authors' institution and the hospital. In addition, verbal consent was obtained from each patient prior to the study.
| Data collection and research tools
We used a questionnaire and the World Health Organization "Mucositis Grading Scale" (WHO, 1979) as data collection instruments. The questionnaire collected data on demographic characteristics (age, gender, weight, height, educational status, profession, smoking status, nutrition, and appetite status), data on the illness and its treatment (diagnosis, time since diagnosis, chemotherapy duration, chemotherapy history and history of OM development, chemotherapy cycle number, chemotherapy regimens, any comorbid disease, prescription of any treatment in addition to chemotherapy and oral complications), and the status of oral care (provided oral care by nurses to prevent mucositis, use of oral care products, and what they are using as oral care products).
A preliminary study assessed the feasibility of the questionnaire, after which it was used in its final form. Patients undergoing preliminary studies were excluded from the study.
The patients were asked to provide detailed information about their demographic characteristics (age, gender, educational status, profession, length, weight, smoking status, nutrition, appetite status) and the status of oral care (use of oral care products and what they are using as oral care products). Information about the patients' general state of health and the oral complications they experienced was obtained from the patients themselves and from their hospital charts.
Clinical data (comorbid disease, diagnosis, chemotherapy regime, chemotherapy duration, number of chemotherapy courses, treatment other than chemotherapy) were obtained from the patients' hospital charts. Nutritional and appetite conditions of the patients were evaluated according to the treatment process. The patients were asked to make a comparison based on their pretreatment status. According to the patients' reports, their nutritional status was described as "regular"
and "irregular" and their appetites as "little appetite", "normal appetite", and "voracious appetite". The weight classification of the patients was made according to body mass index (BMI). The body mass index is calculated as body weight in kilograms divided by squared body surface area in square meters. Underweight was defined as BMI < 18.5 kg/m 2 . Patients who smoked within the past 3 months were defined as smokers.
| WHO Mucositis Grading Scale
The WHO Mucositis Grading Scale is a simple, easy-to-use measure that is often preferred in studies and suitable for daily use in clinical practice (Hosseinjani et al., 2017; Shillingburg et al., 2017; Vagliano et al., 2011) . The WHO rating scale measures oral mucositis in terms of its anatomical, symptomatic, and functional components. In this classification, OM is graded as 0 (normal), 1 (mild focal changes [erythematous areas] that are not yet painful or sensitive; oral intake is possible), 2 (painless ulcers, erythema, and only mild pain), 3 (painful erythema, oedema, or ulcers of depth > 2 mm covering less than half of the mucosa; no bleeding; and the taking of only a liquid diet orally), and 4 (erythema, oedema, or ulcers covering more than half of the mucosa; severe pain; bleeding; not taking nutrition orally [parenteral and enteral nutrition support required]).
| Oral examination
Patients were briefed on the intraoral examination. Using a light source, the inner parts of the mouth (the inner lips, the entire surface of the tongue, and the oral and buccal mucosa) were examined.
| Mucosa
Each patient was told to slowly and gently open her/his mouth, and both lips were pulled away from the teeth. The mucosa was observed in terms of colour (pink, red), hydration (dry, wet), structure (complete, degraded), and lesions (ulcers, abrasions, or cysts). Some lesions were palpated with a gloved finger to determine sensitivity, size, and density.
| Tongue, soft palate, and oral base
Patients were told to protrude half of their tongue; the upper surface of the tongue was assessed in terms of colour, texture, lesions, and any coating. To assess the lower surface of the tongue and the mouth floor, each patient was told to flatten the tongue against the upper palate. Then, to assess the soft palate, the patients were told to bring their tongues back to their original position. The exposed regions were evaluated in terms of colour, swelling, and lesions such as cysts. Since no signs of cysts were found in the intraoral examination, no assessment was made in this context.
The same investigator conducted all of the examinations to eliminate interobserver variability. Intraoral assessment was performed only once and during the time the patients were receiving chemotherapy. All results were recorded using the Mucositis Grading Scale.
| Data analysis
All data were evaluated using Statistical Package for Social Sciences software version 13.0. The study sample was assessed in terms of their sociodemographic and illness-related and treatment-related descriptive statistics (frequency, mean, and standard deviation). Prior to the analysis, the continuous and discrete variables in the questionnaire were grouped together, merging together the elements that were too few to analyse. The age variable was categorized into similar age ranges. Since there were only a few patients with a voracious appetite (two individuals), these were grouped together with the group of individuals with normal appetites. As there were only a few patients with a thin weight (four individuals), these were grouped together with the group of individuals with normal weight. As there were only a few smokers (two individuals), these were grouped together with the group of smokers who had quit the habit. The patients who were receiving four or more courses of chemotherapy were gathered together in a single group. The chi-squared test was used to evaluate the significance of between-group differences.
Multivariable logistic regression analysis was used to define the predictors associated with oral mucositis in patients receiving chemotherapy for cancer. In the model, the dependent variable was OM, and the independent variables were entered one after another as age, appetite, diagnosis, and chemotherapy duration.
A difference was considered significant at P < 0.05.
| RESULTS
A total of 147 patients were enrolled in this study. Patients' ages ranged from 30 to 80 years with mean (SD) of 53.70 (11.18) years; 61.9% were female, 51.7% had primary school education only, 49.7% did not smoke, 77% had a regular diet and ate properly, 72.1% had a normal appetite, 36.7% were overweight, and 34% had a comorbid disease, the most common of which was hypertension (70%) and diabetes mellitus Cisplatin + xeloda, cisplatin + herceptin, taxol + cisplatin, taxol + carboplatin, taxoter + carboplatin, taxoter + cisplatin, cisplatin + etoposid + carboplatin, xeloda + carboplatin, cisplatin + 5-FU, carboplatin + paclitaxel, cisplatin + navelbine, gemcitabine + cisplatin, gemcitabine + carboplatin.
d Cisplatin, taxol, taxoter, folinic acid, herceptin, gemcitabine, taxol + herceptin, taxoter + herceptin, taxoter + epirubicin, taxoter + xeloda, pemetrexed, halaven, CA (cyclophosphamide + adriablastin), epirubicin + endoxan, tomudex, CE (cyclophosphamide + epirubicin), XELOX (oxaliplatin + xeloda), gemcitabin + abraxane, bondronat, bondronat + navelbine, gemcitabine + navelbine, adriablastin + endoxan, irinotecan + cetuximab.
e More than one answer is given.
f Carbonated/salty water (11), tantum (2), listerine (1), likarba (1), herbal tea (1), chlorhexidine (1), do not know (11).
(32%). The patients had breast cancer (47.6%), gastrointestinal cancer (38.8%), and lung cancer (13.6%). The time since diagnosis was less than 1 year for 68% of patients, and chemotherapy duration was 1 to were not using any prescribed or over-the-counter oral care product because they had not been advised to do so by the health care staff (81%) ( Table 1 ).
The incidence of OM was 51.7%, and 81.6% of patients with OM had stage 1 OM (Figure 1 ). Patients included in the study reported that they suffered from dry mouth (55.1%), a reduced/changed sense of taste (52.4%), a lack of appetite (47.6%), dry and cracked lips (41.5%), thirst (20.4%), hoarseness (18.4%), bad breath (13.6%), difficulty swallowing (11.6%), eating difficulties (7.5%), ulceration (5.4%), pain (4.8%), difficulty speaking (4.8%), erythema (4.8%), a burning sensation (4.1%), and bleeding (1.4%) (Figure 2 ).
OM was significantly more frequent in patients who advanced age and decreasing appetite and suffered from other oral problems caused by chemotherapy (P < 0.05) ( Table 2 ). We performed logistic regression analysis to detect factors that might affect OM status. We found that 20.1% of OM was explained by age, appetite status, diagnosis, and the extent of CT. The risk of OM increased with age, a lack of appetite, and a chemotherapy duration of 1 to 3 months (P = 0.038, OR = 1.037, CI = 1.002-1.073; P = 0.030, OR = 2.523, CI = 1.092-5.832; and P = 0.005, OR = 3.542, CI = 1.472-8.520, respectively). We found no significant difference in terms of OM incidence among the diagnostic groups evaluated by logistic regression (P > 0.05) (Table 3) .
| DISCUSSION
We examined the incidence, the stage and risk factors of OM, and the incidence of other oral complications in patients receiving outpatient chemotherapy.
Most studies on OM incidence and severity have been on cancer patients receiving chemotherapy on an inpatient basis, and these studies have reported an OM incidence of 22.3% to 71.7% (Cheng et al., 2010; Maree, Combrink, Lange, Toerien, & Bedeker, 2011; Mercadante et al., 2015; Nishimura et al., 2012) . Half of our current patients (51.7%) had OM, the incidence of which was higher (75.4%) in another study on outpatients (Chen, 2008) . Most OM patients (81.9%) had grade 1 OM (17.1% and 1.3% had grades II and III, respectively). The rates reported in the literature vary widely (Elting et al., 2003; Kim et al., 2012; Wilberg et al., 2014) .
We found that the most common oral complications were dry mouth, a reduced/changed sense of taste, a lack of appetite, dry and cracked lips, and thirst (55.1%, 52.4%, 20.4%, 41.5%, and 47.6% of patients, respectively). Wilberg et al. (2014) and Cheng (2007) FIGURE 1 Incidence and severity of oral mucositis (n = 147)
FIGURE 2 Distribution of oral complications reported that patients undergoing chemotherapy most commonly experienced a dry mouth and taste changes, similar to our findings (Cheng, 2007; Wilberg et al., 2014) .
Comorbidities may also have affected the development of oral complications. Certain systemic diseases and medications reduce saliva volume, creating a risk of xerostomia and other oral complications.
Comorbid conditions and drugs prescribed other than for chemotherapy
were not risk factors for OM development, as previously reported by McCarthy et al. (McCarthy, Awde, & Ghandi, 1998) . In the present study, it was determined that comorbidity was not a risk factor for OM.
Many complications develop in cancer patients; cancer is a chronic disease requiring long-term treatment. Oral complications are no exception, and complications increase in number as treatment is prolonged. However, we found that the time since diagnosis was not a risk factor for OM. Although OM was noted in most patients with lung cancer, the type of cancer did not significantly affect OM incidence. Similarly, Kim et al. (2012) found no significant relationship between diagnostic groups in terms of OM (Kim et al., 2012) . In contrast, Nishimura et al. (2012) reported that the OM incidence was higher in patients with breast cancer (Nishimura et al., 2012) .
The reason for the different results from the studies may be due to the fact that the diagnoses of the patients referred to different stages and the treatment protocols of the patients were different.
Our regression analysis showed that advanced age increased the OM risk by 1.03-fold (P < 0.05). Wuketich et al. (2012) described similar results (Wuketich et al., 2012) . However, other studies found that OM was more common in younger patients (Kim et al., 2012) or found no relationship between age and OM incidence (Vokurka et al., 2006) .
Female gender was a risk factor for OM in two studies whereas we found that OM incidence was higher in males but the difference was not statistically significant (Goldberg, Chiang, & Selina, 2004; Vokurka et al., 2006) .
Although the incidence in those of lower educational status was somewhat higher, educational status was not significantly related with OM incidence. It might be surmised that the cause of oral mucositis was independent of the individual's educational status. Cigarette smoke has proinflammatory effects on the oral mucosa (Lerner, Weiner, Katz, Reznick, & Pollack, 2009 ). More than half of all patients who smoked or who had previously smoked developed OM, but the difference between this group and nonsmokers was not significant.
In contrast, Goldberg et al. (2004) reported that smoking history was significantly associated with OM incidence (Goldberg et al., 2004) .
OM caused by chemotherapy, and other secondary oral complications, can considerably restrict oral food intake (Radha & Namrata, 2014) . Patients with OM may exhibit changes in feeding habits, a reduced appetite, and ultimately malnutrition. As OM advances, so does the severity of malnutrition (Sadasivan, 2010 ). In the current study, we found that appetite status influenced OM frequency; more than half of those with poor appetites developed OM. Regression analysis showed that poor appetite increased the risk of OM by 2.5-fold.
Chemotherapy agents cause side effects in patients that affect the GI tract such as nausea, dryness of the mouth, changes in taste sensations, and loss of appetite, leading to malnutrition (Cheng, 2007) . We found that more than half of all patients who experienced oral complications (56.7%) during chemotherapy had OM; this was statistically significant. Wilberg et al. (2014) found that 19% of patients with oral problems had grade 1 to 2 OM, similar to what we found, and patients with and without oral problems differed significantly in terms of OM incidence (Wilberg et al., 2014) .
Some studies have suggested that the number of chemotherapy cycles affects OM development (Goldberg et al., 2004; Kim et al., 2012) . Although more than half of our patients who had undergone four or more chemotherapy courses developed OM, neither the number of chemotherapy courses nor the treatment regimen was a risk factor for OM. Previous studies have found that OM is more frequent in patients receiving combination 5-FU treatments (Nishimura et al., 2012; Wilberg et al., 2014) .
We found that the incidence of OM tended to be higher in patients with prior histories of chemotherapy, although statistical significance was not attained. Similarly, Nishimura et al. (2012) found that the incidence of OM was not associated with a prior chemotherapy history (Nishimura et al., 2012) .
The first biological response to the toxic effects of chemotherapy begins a short while after chemotherapy begins and starts in the submucosa and a clinical symptom of mucositis is not discernible at that time (Treister & Sonis, 2007) . We found that over half of all patients who had undergone chemotherapy for 1 to 3 months had OM; longer duration chemotherapy increased the OM risk 3.5-fold.
OM treatment includes pain reduction, maintenance of nutrition, and good oral hygiene (McGuire et al., 2013) . We did not find evidence for any benefit afforded by use of oral care products (including carbonated/salty water, tantum, Listerine, Likarba, herbal tea, chlorhexidine, or others). This result is related to the more common use of oral care products among patients with mucositis.
Similarly, Salvador, Azusano, Wang, and Howell (2012) have reported that oral care protocols alone appear not to be beneficial (Salvador et al., 2012) . The findings of the study will contribute to improving both nursing care and training as well as the treatment offered to cancer patients.
| Limitations of the study
Limitations of the study are that OM was evaluated only in patients who were undergoing at least their second round of chemotherapy, and then only once by researchers. Reliability was not tested by a third person. There were not any strategies applied to determine intrarater and interrater reliability. Each patient has also different treatment procedures and individual differences in taking care of their own. Data related to oral mucositis were collected with WHO Scale and oral examination methods and were based on patients' oral statements.
Other limitations were that the date the oral mucositis started was not assessed and a dentist was not included in the study.
| CONCLUSIONS
This study evaluated the frequency of OM and other oral complications in individuals receiving outpatient chemotherapy. We found that half of all patients undergoing outpatient chemotherapy had OM. The majority of patients with oral mucositis had stage 1 OM. The most frequently experienced oral complications were dry mouth, a change in the sense of taste, hoarseness, and difficulty eating. The important risk factors for OM development were advanced age, a lack of appetite, and the duration of chemotherapy. Nurses should be trained and supported in using the clinical care guides that are specific to and of critical importance in the field of oncology.
